Oncology

Featured

Conference Coverage

Exciting Developments and Novel Targets in Chronic Lymphocytic Leukemia Treatment

10/21/2024

Alexey Danilov, MD, reviews the latest exciting developments in the chronic lymphocytic leukemia clinical research landscape, highlighting BTK and BCL2 inhibitors as well as BTK degraders.

Alexey Danilov, MD, reviews the...

10/21/2024

Oncology

Conference Coverage

Selecting Optimal Frontline Therapies for Treating Patients With CLL

10/21/2024

Alexey Danilov , MD;

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.

At the 2024 Lymphoma, Leukemia &...

10/21/2024

Oncology

Conference Coverage

First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

10/21/2024

Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.

Benjamin Besse, MD, PhD,...

10/21/2024

Oncology

Conference Coverage

Utilizing CAR T-Cell Therapy to Treat Patients With R/R Follicular Lymphoma

10/19/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.

At the 2024 Lymphoma, Leukemia &...

10/19/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating the Use of MRD in Multiple Myeloma Treatment

10/19/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.

At the 2024 Lymphoma, Leukemia &...

10/19/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Use of Targeted Agents Among Patients With R/R Follicular Lymphoma

10/18/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.

At the 2024 Lymphoma, Leukemia &...

10/18/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation

10/18/2024

Craig Sauter , MD;

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...

At the 2024 Lymphoma, Leukemia &...

10/18/2024

Oncology

Videos

Managing Oral Toxicities Among Patients With R/R MM Receiving Talquetamab Therapy

10/18/2024

Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.

Beth Faiman PhD, MSN, provides...

10/18/2024

APP Institute Oncology

From APP Institute Oncology

Conference Coverage

Optimizing Treatment Methods Among Patients With Newly Diagnosed AML

10/17/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...

At the 2024 Lymphoma, Leukemia &...

10/17/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

Alberto Montero, MD, UH Seidman Cancer Center

Videos

STX-478 Demonstrates Promise in Heavily Pre-Treated Patients With PI3Kα-Mutated Solid Tumors

10/17/2024

Alberto Montero , MD;

Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.

Alberto Montero, MD, discusses...

10/17/2024

Oncology

Conference Coverage

Exploring Diagnostic Criteria and Treatment Options for Patients With CMML

10/17/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.

At the 2024 Lymphoma, Leukemia &...

10/17/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

https://www.hmpgloballearningnetwork.com/site/onc-app

Insights From the ESMO Congress

Videos

STX-478 Demonstrates Promise in Heavily Pre-Treated Patients With PI3Kα-Mutated Solid Tumors

10/17/2024

Alberto Montero , MD;

Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.

Alberto Montero, MD, discusses...

10/17/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Sustains Clinical Benefit for Patients With Resected Stage IIB/IIC Melanoma

10/07/2024

Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.

Georgina Long, MD, PhD,...

10/07/2024

Oncology

Conference Coverage

Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer

10/04/2024

Stephanie Holland ;

Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...

Landmark 4-year analysis results...

10/04/2024

Oncology

Conference Coverage

Darolutamide Demonstrates Efficacy and Safety for Metastatic Hormone-Sensitive Prostate Cancer

10/02/2024

Fred Saad , MD;

Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Fred Saad, MD, discusses results...

10/02/2024

Oncology

News

Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer

10/02/2024

Allison Casey ;

The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.

The phase 3 SAKK 41/13 trial...

10/02/2024

Oncology

Conference Coverage

Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer

10/01/2024

Stephanie Holland ;

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

According to interim analysis...

10/01/2024

Oncology

Conference Coverage

Prolonged Efficacy of Encorafenib Plus Binimetinib for Metastatic BRAF V600E-Mutant Non-Small Cell Lung Cancer

10/01/2024

Allison Casey ;

According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.

According to updated data from...

10/01/2024

Oncology

Conference Coverage

Neoadjuvant Immune Checkpoint Inhibitors Extend Survival Among Patients With Advanced Melanoma

10/01/2024

Georgina Long, MD, PhD, discusses updated pooled analysis results from the International Neoadjuvant Melanoma Consortium which identified that neoadjuvant immunotherapy extends survival in patients with advanced melanoma.

Georgina Long, MD, PhD,...

10/01/2024

Oncology

Conference Coverage

Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

09/25/2024

Stephanie Holland ;

According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...

According to exploratory results...

09/25/2024

Oncology

Conference Coverage

Nivolumab Sustains Clinical Benefit Among Patients With Resectable Non-Small Cell Lung Cancer

09/25/2024

Stephanie Holland ;

According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.

According to updated results...

09/25/2024

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases

08/02/2024

Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.

Rene Adam, MD, PhD, discusses...

08/02/2024

Oncology

Videos

Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Eligible Patients With Newly Diagnosed MM

07/27/2024

Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.

Paula Rodríguez-Otero, MD,...

07/27/2024

Oncology

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/22/2024

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses...

07/22/2024

Oncology

Conference Coverage

Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer

07/19/2024

David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

David Spigel, MD, discusses the...

07/19/2024

Oncology

Conference Coverage

Regorafenib Plus Pembrolizumab Among Patients With Advanced Hepatocellular Carcinoma Previously Exposed to Immunotherapy

07/18/2024

Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...

Anthony El-Khoueiry, MD,...

07/18/2024

Oncology

News

Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases

07/18/2024

Allison Casey ;

According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.

According to the phase 3...

07/18/2024

IO Learning

Conference Coverage

Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM

07/02/2024

At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.

At the 2024 ASCO Annual Meeting,...

07/02/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab As Potential New Frontline Option for Patients With Unresectable Hepatocellular Carcinoma

07/02/2024

Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.

Peter Galle, MD, PhD, discussed...

07/02/2024

Oncology

Conference Coverage

Neoadjuvant Dostarlimab for Patients With Locally Advanced Mismatch Repair Deficient Rectal Cancer

07/01/2024

Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.

Andrea Cercek, MD, discussed...

07/01/2024

Oncology

Conference Coverage

Gemcitabine and Nab-Paclitaxel vs 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Metastatic Pancreatic Ductal Adenocarcinoma

06/28/2024

Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.

Efrat Dotan, MD, discussed...

06/28/2024

Oncology

Biological Pathway Reviews

Live Meetings

Recent News

News

Novel EGFR x HER3 Bispecific Antibody-Drug Conjugate Shows Promise Among Heavily-Pretreated Patients With Advanced Urothelial Carcinoma

10/21/2024

Allison Casey ;

A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.

A novel EGFR x HER3 bispecific...

10/21/2024

Oncology

News

Amivantamab Plus Chemotherapy Numerically Improved OS for Patients with EGFR-Mutant, Advanced NSCLC

10/21/2024

Allison Casey ;

According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung...

According to second interim data...

10/21/2024

Oncology

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology